Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Urologix (ULGX) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 30
  • Shares Outstanding, K 21,820
  • Annual Sales, $ 14,240 K
  • Annual Income, $ -7,610 K
  • 36-Month Beta 4.16
  • Price/Sales N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0010 +30.00%
on 11/15/16
0.0034 -61.76%
on 11/18/16
+0.0003 (+30.00%)
since 11/03/16
3-Month
0.0010 +30.00%
on 11/15/16
0.0034 -61.76%
on 11/18/16
-0.0003 (-18.75%)
since 09/06/16
52-Week
0.0010 +30.00%
on 11/15/16
0.0170 -92.35%
on 12/09/15
-0.0137 (-91.33%)
since 12/04/15

Most Recent Stories

More News
Urologix Announces Sale of Operating Assets to Private Company Buyer

Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today that as of the close of business on January 29, 2015 substantially...

Global Prostrate Specific Antigen (PSA) Testing Market Analysis 2015-2020 - Free PSA Test, Complex PSA Test, Reverse PCR Test

Research and Markets (http://www.researchandmarkets.com/research/n53fd7/prostrate) has announced the addition of the "Prostrate Specific Antigen (PSA) Testing Market Analysis (2015 - 2020); By Type (Free...

Urologix Announces SEC Deregistration

Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of...

Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans

Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral...

Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans

Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association...

Urologix Announces Hiring of Chief Financial Officer

Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial...

Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call

Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release...

Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call

Urologix, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Support & Resistance

2nd Resistance Point 0.0016
1st Resistance Point 0.0014
Last Price 0.0013
1st Support Level 0.0012
2nd Support Level 0.0012

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.